
Xspray Pharma Q1 2025 - All eyes on PDUFA

Redeye comments on Xspray following an undramatic Q1 report. The key focus remains on the ongoing regulatory process and launch preparations for Dasynoc, alongside the continued clinical development of XS003.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Xspray Pharma Q1 2025 - All eyes on PDUFA